Kisspeptin + BPC-157 + Thymosin Alpha-1 Women's Hormonal Optimization Stack

Kisspeptin-10: 1-5 mcg/kg subcutaneously, administered in the morning. Kisspeptin stimulates GnRH neurons in the hypothalamus, restoring the pulsatile LH and FSH signaling that drives ovarian hormone production. Start at the lower end of the dose range (1 mcg/kg) and titrate based on hormonal response. Kisspeptin is typically used 5 days on, 2 days off, or on a cyclic schedule aligned with the menstrual cycle (follicular phase dosing for ovulation support). For women with hypothalamic amenorrhea, daily dosing for 2-4 weeks followed by hormonal reassessment is a common investigational approach.

BPC-157: 250-500 mcg subcutaneously once daily, administered in the morning or split into two doses (morning and evening). BPC-157 addresses the gut-hormone connection — intestinal permeability, gut inflammation, and dysbiosis disrupt estrogen metabolism (estrobolome), cortisol regulation, and nutrient absorption critical for hormone synthesis. The lower abdominal injection site is commonly used.

Thymosin Alpha-1: 1.6 mg subcutaneously twice weekly (e.g., Monday and Thursday). Thymosin alpha-1 modulates immune function — it enhances dendritic cell maturation, promotes balanced Th1/Th2 responses, and supports regulatory T-cell function. For women with autoimmune thyroiditis (Hashimoto's), endometriosis, or PCOS with inflammatory features, immune regulation is directly relevant to hormonal outcomes.

Cycle structure: 8-12 week cycles. Kisspeptin dosing should be aligned with the menstrual cycle when possible — follicular phase administration (days 3-14) supports follicular development and ovulation. BPC-157 and thymosin alpha-1 are used continuously throughout the cycle. Comprehensive hormone panels (LH, FSH, estradiol, progesterone, testosterone, DHEA-S, thyroid panel) at baseline, 4 weeks, and 8 weeks guide dose adjustment.